| Eisai Pharma AG - Inovelon, Suspension zum Einnehmen | | 62066 | | 01 | | Inovelon | | Suspension zum Einnehmen | | N03AF03 | | Rufinamide | | 13.06.2012 | | |
| | Composition | | rufinamidum 40 mg, sorbitolum liquidum non cristallisabile corresp. sorbitolum 175 mg, propylenglycolum 25 mg, cellulosum microcristallinum, carmellosum natricum, acidum citricum, hydroxyethylcellulosum, dimeticonum, polysorbatum 65, methylcellulosum, silica colloidalis hydrica, macrogoli stearas, E 210 max. 0.005 mg, E 200, acidum sulfuricum, poloxamerum 188, aromatica (Orange) cum alcohol benzylicus, E 202, E 218 1.2 mg, propylis parahydroxybenzoas 0.3 mg, aqua purificata, ad suspensionem pro 1 ml corresp. natrium max. 0.22 mg. | | Packungsbestandteile | | Suspension (orale) | | | | | | | | Principe actif | Concentr. |
|---|
| Rufinamidum | 40 mg/ml |
| | BAG: Principe actif | Concentr. |
|---|
| Rufinamidum | 40 mg |
| | | | Agents auxilliaires | | informations additionels |
|---|
| Alcohol Benzylicus | | | | Aromatica | | | | E 202 | | conserv. | | E 218 | | conserv. | | Propylis Parahydroxybenzoas | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 460 ml | 68.01 | 90.40 | B | LS | Oui |
|
|
